Description
Background:
Tigatuzumab is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein with limited expression in normal tissues but overexpressed in many kinds of tumours, including colon, gastric, pancreatic, lung, and cervical
Intended Use:
For Estimation of Tigatuzumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!